Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/19379

Type
Preprint
Copyright
Open access
Sustainable Development Goals
03 Saúde e Bem-Estar
Collections
Share

Statistics
Metadata
Show full item record

ZIKA IN THE AMERICAS, YEAR 2: WHAT HAVE WE LEARNED? WHAT GAPS REMAIN? A REPORT FROM THE GLOBAL VIRUS NETWORK
Aliota, Matthew T. et al. | Date Issued: 2017
Author
Aliota, Matthew T.
Bassit, Leda
Bradrick, Shelton S.
Cox, Bryan
Garcia-Blanco, Mariano A.
Gavegnano, Christina
Friedrich, Thomas C.
Golos, Thaddeus G.
Griffin, Diane E.
Haddow, Andrew
Kallas, Esper Georges
Kitron, Uriel
Lecuit, Marc
Magnani, Diogo M.
Marrs, Caroline
Mercer, Natalia
McSweegan, Edward
Ng, Lisa
O'Connor, David H.
Osorio, Jorge E.
Ribeiro, Guilherme de Sousa
Ricciardi, Michael
Rossi, Shannan L.
Saade, George
Schinazi, Raymond F.
Schott-Lerner, Geraldine O.
Shan, Chao
Shi, Pei-Yong
Watkins, David I.
Vasilakis, Nikos
Weaver, Scott C.
Affilliation
Múltipla - ver em Notas
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia. School of Medicine. Department of Pathology and Forensic Medicine. Salvador, BA, Brazil.
Abstract
In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of Zika in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary Zika virus disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.
Keywords in Portuguese
Vírus Zika
Arbovírus
Manifestações congênitas
Transmissão materno-fetal
Terapia antiviral
Vacinas
 
Keywords
Zika virus
Arbovirus,
Congenital manifestations
Maternal-fetal transmission
Antiviral therapy
Vaccines
 
Publisher
Elsevier Masson
Citation
ALIOTA, M. T. et al. Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. Antiviral Research, 2017.
DOI
10.1016/j.antiviral.2017.06.001
ISSN
0166-3542
Notes
Ribeiro, Guilherme de Sousa. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Saúde Coletiva. Salvador, BA, Brazil. aDepartment of Pathobiological Sciences, University of Wisconsin-Madison bCenter for AIDS Research, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA cDepartment of Biochemistry and Molecular Biology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA dWisconsin National Primate Research Center, University of Wisconsin-Madison. eDepartment of Comparative Biosciences, University of Wisconsin-Madison. fDepartment of Obstetrics and Gynecology, University of Wisconsin-Madison. gW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205 hVirology Division. United States Army Medical Research Institute of Infectious Diseases. Ft. Detrick, MD 21702 iDivision of Clinical Immunology and Allergy, School of Medicine, University of São Paulo jDepartment of Environmental Sciences, Emory University, Atlanta, Georgia, USA kInstitut Pasteur, Biology of Infection Unit and INSERM Uni 1117 LParis Descartes University, Sorbonne Paris Cité, and Division of Infectious Diseases and Tropical Medicine, Necker– Enfants Malades University Hospital, Institut Imagine, Paris, France mDepartment of Pathology, University of Miami, Miami, FL, USA. nDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA oSingapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore pDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison qInstituto Gonçalo Moniz, Fundação Oswaldo Cruz and Instituto de Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia, Brazil r*Department of Microbiology & Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA sDepartment of Pathology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA